MoonLake Immunotherapeutics
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
MLTX$12.62+9.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes In E
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Class A Ordinary Shares · Class C Ordinary Shares · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders' Equity · Noncontrolling Interests · Total Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands except share data) · Shares · Amount · Shares · Amount | ||||||||||
| Balance at January 1, 2025 | 63,077,431 | $6 | 841,269 | $— | $677,415 | $(235,593) | $4,997 | $446,825 | $6,566 | $453,391 |
| Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan | — | — | — | — | 2,279 | — | — | 2,279 | 11 | 2,290 |
| Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares | 111,949 | — | (111,949) | — | 841 | — | 10 | 851 | (851) | — |
| Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee | 93,347 | — | — | — | 129 | — | — | 129 | (9) | 120 |
| Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan | 191,526 | — | — | — | — | — | — | — | — | — |
| Net loss for the three months ended March 31, 2025 | — | — | — | — | — | (39,944) | — | (39,944) | (615) | (40,559) |
| Other comprehensive loss | — | — | — | — | — | — | (2,620) | (2,620) | (41) | (2,661) |
| Balance at March 31, 2025 | 63,474,253 | $6 | 729,320 | $— | $680,664 | $(275,537) | $2,387 | $407,520 | $5,061 | $412,581 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Class A Ordinary Shares · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders' Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands except share data) · Shares · Amount | ||||||
| Balance at January 1, 2026 | 71,373,579 | $7 | $766,781 | $(462,911) | $604 | $304,481 |
| Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan | — | — | 13,355 | — | — | 13,355 |
| Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan | 354,296 | — | — | — | — | — |
| Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan | 69,632 | — | 170 | — | — | 170 |
| Issuance of Class A Ordinary Shares, net of transaction costs | 336,559 | — | 6,007 | — | — | 6,007 |
| Net loss for the three months ended March 31, 2026 | — | — | — | (69,707) | — | (69,707) |
| Other comprehensive loss | — | — | — | — | (282) | (282) |
| Balance at March 31, 2026 | 72,134,066 | $7 | $786,313 | $(532,618) | $322 | $254,024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.